GBM39 Cell Line NTCC®人原发性胶质母细胞瘤细胞株Human primary glioblastoma tumor cell line BioVector NTCC保藏中心

The NTCC® GBM39 cell line is a human patient-derived xenograft (PDX) model for glioblastoma (GBM). It's a type of cancer cell line that is particularly valuable in research because it closely mimics the characteristics of a patient's tumor, providing a more clinically relevant model than older, established cell lines.

Key Characteristics

• Origin: GBM39 was derived from a primary glioblastoma tumor in a 51-year-old male patient.

• Genetics: The cell line has a specific genetic profile that is important for research. It harbors the EGFRvIII (epidermal growth factor receptor variant III) mutation, a common alteration in glioblastoma that promotes tumor growth and is often resistant to treatment. It also has a methylated TERT promoter and amplification of MDM4 and PIK32B.

• Culture: It's typically cultured as floating cellular spheres (spheroids) in a specialized, serum-free medium to maintain its stem-cell-like properties and prevent differentiation. This mimics the in-vivo behavior of glioblastoma.

• Heterogeneity: The GBM39 line is not entirely uniform. It has a mix of cells, with about 90% having EGFR amplicons on extrachromosomal DNA (ecDNA) and the remaining 10% having them on homogeneously staining regions (HSRs). This heterogeneity makes it a good model for studying the different cellular populations within a real tumor.

Research Applications

The GBM39 cell line is a crucial tool for glioblastoma research, especially in the following areas:

• Preclinical Drug Discovery: Researchers use it to test the effectiveness of new therapies against glioblastoma. Its patient-like characteristics help in predicting how a drug might perform in a clinical setting.

• Therapy Resistance: Because it's derived from a difficult-to-treat cancer, GBM39 is used to study the mechanisms of resistance to standard therapies like temozolomide (TMZ) and radiation.

• Tumor Biology: Scientists study this cell line to better understand the fundamental biology of glioblastoma, including how the EGFRvIII mutation contributes to tumor growth, the role of extrachromosomal DNA in cancer, and the interactions between tumor cells and their microenvironment.

GBM39 细胞系是一种用于胶质母细胞瘤（Glioblastoma, GBM）研究的人源患者肿瘤异种移植（Patient-Derived Xenograft, PDX）模型。这种癌细胞系在研究中非常有价值，因为它能高度模拟患者体内肿瘤的特征，相比传统的、已建立的细胞系，它提供了更具临床相关性的模型。

主要特点

• 来源: GBM39 细胞系是从一名51岁男性患者的原发性胶质母细胞瘤肿瘤中分离建立的。

• 遗传学: 该细胞系具有特定的遗传图谱，这对研究至关重要。它携带 EGFRvIII（表皮生长因子受体 III 型变体）突变，这是胶质母细胞瘤中常见的变异，它能促进肿瘤生长，并常导致对治疗产生耐药性。此外，它还具有甲基化的TERT启动子，以及MDM4和PIK32B的扩增。

• 培养方式: 该细胞系通常在特殊的无血清培养基中以漂浮的细胞球（spheroids）形式进行培养，以维持其干细胞样的特性并防止分化。这种培养方式模拟了胶质母细胞瘤在体内的生长行为。

• 异质性: GBM39 细胞系并非完全同质。它包含多种细胞，其中约90%的细胞在染色体外DNA（ecDNA）上具有EGFR扩增子，而剩余的10%则位于均质着色区（HSRs）上。这种异质性使其成为研究真实肿瘤内不同细胞群体的良好模型。

BioVector NTCC质粒载体菌种细胞基因保藏中心

www.biovector.net